<DOC>
	<DOCNO>NCT00701324</DOCNO>
	<brief_summary>The main objective trial provide safety data term drug-related adverse event ( AE ) recommendation dose trial development BI 811283 . Secondary objective collection antitumour efficacy data determination pharmacokinetic profile BI 811283 .</brief_summary>
	<brief_title>BI 811283 Various Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Patients confirm diagnosis advance , nonresectable and/or metastatic solid tumour , fail conventional treatment therapy proven efficacy exist amenable establish treatment option Secure central venous access Evaluable tumour deposit Recovery reversible toxicity prior anticancer therapy Age &gt; = 18 year Life expectancy &gt; = 6 month Written inform consent accordance International Conference Harmonisation ( ICH ) guideline Good Clinical Practice ( GCP ) local legislation Eastern Cooperative Oncology Group performance score &lt; = 2 Exclusion criterion : Serious illness , concomitant nononcological disease ( e.g . active infectious disease ) , ongoing toxicity prior therapy consider investigator potentially compromise patient ' safety trial Pregnancy breastfeed Known brain metastasis Second malignancy require therapy Left ventricular ejection fraction ( LVEF ) &lt; 50 % echocardiography clinical congestive heart failure New York Heart Association grade III IV Myocardial infarction within last 6 month prior inclusion symptomatic coronary artery disease Absolute neutrophil count less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin great 1.5 mg / dl ( &gt; 26 mcmol / L , SI unit equivalent ) Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg / dl ( &gt; 132 mcmol / L , SI unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Treatment investigational drug another clinical trial within past two week start therapy concomitantly trial Chemo , hormone , radio immunotherapy within past two week start therapy concomitantly trial Patients unable comply protocol Active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>